Position
Creative Planning in Allogene Therapeutics, Inc.
Back to the book · All holders of ALLO
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $292.5K$1.37 → $2.44
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 273.4K | $374.5K | — | — | — | 0.0% |
| Q1 2026 | 364.8K | $890.1K | $2.44 | $292.5K | $223.1K | 0.0% |